Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 222

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 222
---
 |                2,444,985 |   |   |  1,451,686 |   |
| Cash and cash equivalents, beginning of the year                            |   |                1,719,338 |   |   |    267,652 |   |
| Cash and cash equivalents, end of the year                                  |   |                4,164,323 |   |   |  1,719,338 |   |
| Supplemental information                                                    |   |                          |   |   |            |   |
| Cash paid for interest                                                      | $ |                   40,563 |   |   |          - |   |
| Supplemental disclosure of non-cash investing and financing activities      |   |                          |   |   |            |   |
| Right-of-use assets obtained in exchange for lease liabilities              | $ |                  356,805 |   |   |          - |   |
| Accrued interest converted into common shares                               | $ |                   38,462 |   |   |          - |   |
| Issuance costs included in accounts payable                                 | $ |                  265,025 |   |   |          - |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.

F-9</div>

1. Description of business

Medicus Pharma Ltd. (the "Company" or "Medicus Pharma"), formerly Interactive Capital Partners Corporation ("Interactive"), is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

The Company is a public limited Company originally incorporated pursuant to the provisions of the Business Corporations Act (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities. The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada.

Business Combination Agreement

On March 17, 2023, and as amended on May 12, 2023 and August 29, 2023, the Company entered into a Business Combination Agreement ("BCA") with RBx Capital, LP ("RBx") and SkinJect, Inc. ("SkinJect") under which the Company entered into a reverse takeover ("RTO") with SkinJect on September 29, 2023. SkinJect converted all its shares of equity and